Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A M Lincoff

Showing results (81-90 of 116) with videos related to

Pageof 12
Sort By:
Circulation|January 11, 2000
Economic assessment of platelet glycoprotein IIb/IIIa receptor blockade with abciximab and low-dose heparin during percutaneous coronary revascularization: results from the EPILOG randomized trial. Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb/IIIa blockadeA M Lincoff, D B Mark, J E Tcheng, et al.
Journal of the American College of Cardiology|June 1, 1995
Characteristics and consequences of myocardial infarction after percutaneous coronary intervention: insights from the Coronary Angioplasty Versus Excisional Atherectomy Trial (CAVEAT)R A Harrington, A M Lincoff, R M Califf, et al.
Lancet (London, England)|January 15, 2000
Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: results from a multicentre randomised trial. EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for StentingE J Topol, D B Mark, A M Lincoff, et al.
The American Journal of Cardiology|March 7, 2001
Prognostic importance of concomitant heparin with eptifibatide in acute coronary syndromes. PURSUIT Investigators. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin TherapyJ G Peterson, E J Topol, M T Roe, et al.
Circulation|December 6, 2001
Attenuation of rebound ischemia after discontinuation of heparin therapy by glycoprotein IIb/IIIa inhibition with eptifibatide in patients with acute coronary syndromes: observations from the platelet IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trialM A Lauer, P L Houghtaling, J G Peterson, et al.
The American Journal of Cardiology|March 23, 2000
Timing of and risk factors for myocardial ischemic events after percutaneous coronary intervention (IMPACT-II). Integrilin to Minimize Platelet Aggregation and Coronary ThrombosisM C Thel, R M Califf, B E Tardiff, et al.
European Heart Journal|October 18, 2003
Risk of intracranial haemorrhage with combined fibrinolytic and glycoprotein IIb/IIIa inhibitor therapy in acute myocardial infarction. Dichotomous response as a function of age in the GUSTO V trialS Savonitto, P W Armstrong, A M Lincoff, et al.
European Heart Journal|January 17, 2002
Patients with acute coronary syndromes without persistent ST elevation undergoing percutaneous coronary intervention benefit most from early intervention with protection by a glycoprotein IIb/IIIa receptor blockerE Ronner, E Boersma, K M Akkerhuis, et al.
Circulation|July 6, 2000
Pronounced benefit of coronary stenting and adjunctive platelet glycoprotein IIb/IIIa inhibition in complex atherosclerotic lesionsF A Cura, D L Bhatt, A M Lincoff, et al.
European Heart Journal|February 10, 2000
Geographic variability in outcomes within an international trial of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes. Results from PURSUITK M Akkerhuis, J W Deckers, E Boersma, et al.
Pageof 12

Showing results (81-90 of 116) with videos related to

Sort By:
Pageof 12
Circulation|January 11, 2000
Economic assessment of platelet glycoprotein IIb/IIIa receptor blockade with abciximab and low-dose heparin during percutaneous coronary revascularization: results from the EPILOG randomized trial. Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb/IIIa blockadeA M Lincoff, D B Mark, J E Tcheng, et al.
Journal of the American College of Cardiology|June 1, 1995
Characteristics and consequences of myocardial infarction after percutaneous coronary intervention: insights from the Coronary Angioplasty Versus Excisional Atherectomy Trial (CAVEAT)R A Harrington, A M Lincoff, R M Califf, et al.
Lancet (London, England)|January 15, 2000
Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: results from a multicentre randomised trial. EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for StentingE J Topol, D B Mark, A M Lincoff, et al.
The American Journal of Cardiology|March 7, 2001
Prognostic importance of concomitant heparin with eptifibatide in acute coronary syndromes. PURSUIT Investigators. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin TherapyJ G Peterson, E J Topol, M T Roe, et al.
Circulation|December 6, 2001
Attenuation of rebound ischemia after discontinuation of heparin therapy by glycoprotein IIb/IIIa inhibition with eptifibatide in patients with acute coronary syndromes: observations from the platelet IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trialM A Lauer, P L Houghtaling, J G Peterson, et al.
The American Journal of Cardiology|March 23, 2000
Timing of and risk factors for myocardial ischemic events after percutaneous coronary intervention (IMPACT-II). Integrilin to Minimize Platelet Aggregation and Coronary ThrombosisM C Thel, R M Califf, B E Tardiff, et al.
European Heart Journal|October 18, 2003
Risk of intracranial haemorrhage with combined fibrinolytic and glycoprotein IIb/IIIa inhibitor therapy in acute myocardial infarction. Dichotomous response as a function of age in the GUSTO V trialS Savonitto, P W Armstrong, A M Lincoff, et al.
European Heart Journal|January 17, 2002
Patients with acute coronary syndromes without persistent ST elevation undergoing percutaneous coronary intervention benefit most from early intervention with protection by a glycoprotein IIb/IIIa receptor blockerE Ronner, E Boersma, K M Akkerhuis, et al.
Circulation|July 6, 2000
Pronounced benefit of coronary stenting and adjunctive platelet glycoprotein IIb/IIIa inhibition in complex atherosclerotic lesionsF A Cura, D L Bhatt, A M Lincoff, et al.
European Heart Journal|February 10, 2000
Geographic variability in outcomes within an international trial of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes. Results from PURSUITK M Akkerhuis, J W Deckers, E Boersma, et al.
Pageof 12